Veracyte, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $139.1 million for the three months ended March 31, 2026, a 21% increase from $114.5 million in the same period last year. The growth was primarily driven by a 26% rise in testing revenue, which amounted to $135.1 million, up from $107.3 million in the prior year. This increase in testing revenue was attributed to a 19% increase in total test volume, which reached 47,615 tests, alongside improved average selling prices and collections from previous periods. However, biopharmaceutical and other revenue saw a significant decline, dropping to $301,000 from $3.6 million, largely due to the cessation of biopharmaceutical services following the restructuring of Veracyte SAS in August 2025.
The company's gross profit for the quarter was $101.2 million, reflecting a 27% increase compared to $79.5 million in the previous year. Operating expenses rose slightly to $78.5 million from $76.6 million, with notable increases in research and development expenses, which surged by 53% to $27.1 million, driven by investments in product development and clinical studies. In contrast, general and administrative expenses decreased by 30% to $23.7 million, primarily due to the reallocation of certain software development costs to research and development. Veracyte reported a net income of $28.7 million, a substantial increase from $7.0 million in the prior year, resulting in earnings per share of $0.36, compared to $0.09 in the same quarter of 2025.
Operationally, Veracyte's testing volume increased significantly, with 45,248 diagnostic tests reported, up from 38,078 in the previous year. The company continues to focus on expanding its product offerings, including the anticipated launch of the Prosigna test as a laboratory developed test (LDT) in 2026 and the introduction of the TrueMRD platform for minimal residual disease detection. The company is also working on enhancing its international distribution of in vitro diagnostic (IVD) tests, particularly for the Prosigna test.
As of March 31, 2026, Veracyte's cash and cash equivalents, along with short-term investments, totaled $439.1 million, reflecting a $26.2 million increase from the previous quarter. The company generated $35.2 million in cash from operating activities during the quarter, a significant improvement from $5.4 million in the same period last year. Looking ahead, Veracyte anticipates continued revenue growth driven by increased test volumes and successful reimbursement strategies, although it remains cautious about potential macroeconomic challenges and their impact on operations and liquidity.
In summary, Veracyte's strong financial performance in the first quarter of 2026 highlights its successful growth strategy and operational efficiency, despite challenges in certain revenue streams. The company is well-positioned to capitalize on its expanding product portfolio and market opportunities in the diagnostics sector.
About VERACYTE, INC.
Veracyte, Inc. is a global diagnostics company specializing in molecular tests for cancer and lung diseases. Its core offerings include genomic classifiers for thyroid, prostate, bladder, and lung cancers, delivered via CLIA labs and international in vitro diagnostic products. The company leverages AI, bioinformatics, and extensive clinical data to improve diagnosis, prognosis, and treatment decisions, aiming to enhance patient outcomes and reduce unnecessary procedures.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.